Natco Pharma, a Rs.525 crore plus Hyderabad based pharma entity, has reported strong growth in top line as well as bottom line during the third quarter ended December 2012 on account of higher exports of APIs and formulations and the management declared interim dividend of 40 per cent for the year 2012-12.  Its consolidated net profit jumped by 32.9 per cent to Rs.22.59 crore from Rs.17 crore in the corresponding period of last year. EBDITA also moved up by 62.4 per cent to Rs.51.17 crore from Rs.31.50 crore. Its consolidated net sales went up by 22 per cent to Rs.157.78 crore from Rs.129.31 crore. With smart growth in profits, its earnings per share improved to Rs.7.20 from Rs.5.91 in the last period.

The sales of bulk chemicals increased by 56 per cent to Rs.67.43 crore during the quarter under review from Rs.43.22 crore in the similar period of last year and that formulations increased by 4 per cent to Rs.69.82 crore from Rs.66.83 crore.

For the nine months ended December 2012, Natco's net sales increased by 30.2 per cent to Rs.466.31 crore from Rs.358.21 crore in the same period of last year. Its net profit surged by 28.9 per cent to Rs.60.54 crore from Rs.46.96 crore and EBDITA by 39.7 per cent to Rs.126.23 crore from Rs.90.38 crore. The sales of bulk drugs moved up by 35.1 per cent to Rs.171.30 crore from Rs.126.81 crore in the similar period of last year and that of formulations by 16.4 per cent to Rs.217.95 crore from Rs.186.41 crore.